Cargando…

Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case–control study

BACKGROUND: Nosocomial bloodstream infection (nBSI) is an important clinical concern among COVID-19 hospitalised patients. It can cause sepsis and septic shock leading to high morbidity, mortality, and the emergence of antibiotic resistance. The aim of this case–control study is to identify the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Codina-Jiménez, Carla, Marin, Sergio, Álvarez, Marlene, Quesada, Maria Dolores, Rodríguez-Ponga, Beatriz, Valls, Ester, Quiñones, Carles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899639/
https://www.ncbi.nlm.nih.gov/pubmed/34400550
http://dx.doi.org/10.1136/ejhpharm-2021-002776
_version_ 1784663957016936448
author Codina-Jiménez, Carla
Marin, Sergio
Álvarez, Marlene
Quesada, Maria Dolores
Rodríguez-Ponga, Beatriz
Valls, Ester
Quiñones, Carles
author_facet Codina-Jiménez, Carla
Marin, Sergio
Álvarez, Marlene
Quesada, Maria Dolores
Rodríguez-Ponga, Beatriz
Valls, Ester
Quiñones, Carles
author_sort Codina-Jiménez, Carla
collection PubMed
description BACKGROUND: Nosocomial bloodstream infection (nBSI) is an important clinical concern among COVID-19 hospitalised patients. It can cause sepsis and septic shock leading to high morbidity, mortality, and the emergence of antibiotic resistance. The aim of this case–control study is to identify the risk factors associated with the nBSI development in COVID-19 hospitalised patients and its incidence. METHODS AND ANALYSIS: A retrospective case–control study will be performed. Cases will include nBSI episodes of adult patients (≥18 years) admitted to Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, from April to December 2020 with a diagnosis of SARS-CoV-2 pneumonia. Patients transferred from other hospitals will be excluded. Controls will include hospitalisation episodes of COVID-19 patients without nBSI. We will recruit a minimum of 74 nBSI episodes (cases) and 74 controls (according to sample size calculation). We will collect data on sociodemographics, clinical status at admission, hospital admission, in-hospital mortality, and exposure data (use of antivirals, glucocorticoids or immunomodulatory agents, length of hospitalisation, and use of medical devices such as intravenous catheters). A bivariate and a subsequent multivariate regression analysis will be performed to assess the independent effect of the associated risk factors after adjusting for confounders. The nBSI incidence rate will be estimated according to the number of nBSI episodes in admitted COVID-19 patients among the total person-month of follow-up. ETHICS AND DISSEMINATION: The protocol of this study was approved by the Ethical Committee for Drug Investigation of the Hospital Universitari Germans Trias i Pujol. The results of this case–control study will be published in a peer reviewed journal.
format Online
Article
Text
id pubmed-8899639
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88996392022-03-22 Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case–control study Codina-Jiménez, Carla Marin, Sergio Álvarez, Marlene Quesada, Maria Dolores Rodríguez-Ponga, Beatriz Valls, Ester Quiñones, Carles Eur J Hosp Pharm Protocol BACKGROUND: Nosocomial bloodstream infection (nBSI) is an important clinical concern among COVID-19 hospitalised patients. It can cause sepsis and septic shock leading to high morbidity, mortality, and the emergence of antibiotic resistance. The aim of this case–control study is to identify the risk factors associated with the nBSI development in COVID-19 hospitalised patients and its incidence. METHODS AND ANALYSIS: A retrospective case–control study will be performed. Cases will include nBSI episodes of adult patients (≥18 years) admitted to Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, from April to December 2020 with a diagnosis of SARS-CoV-2 pneumonia. Patients transferred from other hospitals will be excluded. Controls will include hospitalisation episodes of COVID-19 patients without nBSI. We will recruit a minimum of 74 nBSI episodes (cases) and 74 controls (according to sample size calculation). We will collect data on sociodemographics, clinical status at admission, hospital admission, in-hospital mortality, and exposure data (use of antivirals, glucocorticoids or immunomodulatory agents, length of hospitalisation, and use of medical devices such as intravenous catheters). A bivariate and a subsequent multivariate regression analysis will be performed to assess the independent effect of the associated risk factors after adjusting for confounders. The nBSI incidence rate will be estimated according to the number of nBSI episodes in admitted COVID-19 patients among the total person-month of follow-up. ETHICS AND DISSEMINATION: The protocol of this study was approved by the Ethical Committee for Drug Investigation of the Hospital Universitari Germans Trias i Pujol. The results of this case–control study will be published in a peer reviewed journal. BMJ Publishing Group 2022-03 2021-08-16 /pmc/articles/PMC8899639/ /pubmed/34400550 http://dx.doi.org/10.1136/ejhpharm-2021-002776 Text en © European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
spellingShingle Protocol
Codina-Jiménez, Carla
Marin, Sergio
Álvarez, Marlene
Quesada, Maria Dolores
Rodríguez-Ponga, Beatriz
Valls, Ester
Quiñones, Carles
Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case–control study
title Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case–control study
title_full Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case–control study
title_fullStr Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case–control study
title_full_unstemmed Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case–control study
title_short Risk factors for nosocomial bloodstream infections in COVID-19 affected patients: protocol for a case–control study
title_sort risk factors for nosocomial bloodstream infections in covid-19 affected patients: protocol for a case–control study
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899639/
https://www.ncbi.nlm.nih.gov/pubmed/34400550
http://dx.doi.org/10.1136/ejhpharm-2021-002776
work_keys_str_mv AT codinajimenezcarla riskfactorsfornosocomialbloodstreaminfectionsincovid19affectedpatientsprotocolforacasecontrolstudy
AT marinsergio riskfactorsfornosocomialbloodstreaminfectionsincovid19affectedpatientsprotocolforacasecontrolstudy
AT alvarezmarlene riskfactorsfornosocomialbloodstreaminfectionsincovid19affectedpatientsprotocolforacasecontrolstudy
AT quesadamariadolores riskfactorsfornosocomialbloodstreaminfectionsincovid19affectedpatientsprotocolforacasecontrolstudy
AT rodriguezpongabeatriz riskfactorsfornosocomialbloodstreaminfectionsincovid19affectedpatientsprotocolforacasecontrolstudy
AT vallsester riskfactorsfornosocomialbloodstreaminfectionsincovid19affectedpatientsprotocolforacasecontrolstudy
AT quinonescarles riskfactorsfornosocomialbloodstreaminfectionsincovid19affectedpatientsprotocolforacasecontrolstudy